Sun Will Face Uphill Struggle To Return To Growth
Pharma & Healthcare / India / Wed 23 Aug, 2017
Sun Pharmaceutical Industries will face an uphill struggle in its new fiscal year to return to sales growth, and of particular concern will be the net loss recorded in Q118. Issues in both India and the US, the firm's two largest markets, have hampered Sun, but the situation in the US is especially pressing. Revitalising its presence in the US will